Krsnaa Diagnostics is an integrated radiology and pathology provider built around long-term government PPP contracts, with 190+ CT/MRI centers, 147 pathology labs, 4,700+ patient collection centers, and a retail network of 3,500+ touch points across 18 states. It prices 50-70% below private market rates and still earned a 27.81% full-year FY26 EBITDA margin, with Q4 FY26 at 29%, which is exceptional for diagnostics and points to a fixed-cost asset base that can absorb volume without proportionate cost. The competitive set in pan-India PPP radiology is small; management claims the largest deployed CT/MRI fleet in Asia and 14 years with virtually no bad debt, so this niche does not resemble a fragmented commodity market.
The economics persist because a statewide PPP contract requires a heavy upfront build: equipment procurement on deferred payment with 20-25% initial outlay, 350+ radiologists and 100+ pathologists, NABL and NABH accreditations, and a delivery logistics network across districts. Competitors cannot replicate this overnight; the company has taken 14 years to assemble an integrated radiology and pathology platform, and it holds first-mover accreditations such as India's first ACR-accredited tele-radiology hub and the first CAP-accredited pathology lab in a government facility. Switching costs are embedded in multi-year concessions and in the operational dependency of state health systems. The caveat is that revenue is concentrated in government payors, and receivables have been a recurring friction; at Q4 FY26 DSO was 139 days, down from 155 days in Q3, with a sub-120 day target for FY27.
The inflection is the simultaneous commissioning of Rajasthan and Maharashtra capacity. Rajasthan installation is expected to complete by Q2 FY27, with conservative FY27 revenue guidance of INR100-150 crores on a full-year basis; the project consumed front-loaded manpower of about 5,000 people in its first year and was marginally EBITDA-negative, but it is expected to reach consolidated-level margins by end FY27. Ten of 17 new MRI centers under the Maharashtra radiology project are scheduled to go live in Q1 FY27, with revenue recognition beginning in Q4 FY26 or in FY27. By 18-24 months out, the business should have a larger retail mix: retail grew from roughly INR10 crores in FY25 to INR60 crores in FY26, about 6x, and is expected to reach double-digit revenue share in FY27, with a long-term aspiration of 25-30% in 3-5 years, and retail itself should be past breakeven after hitting that target around Q4 FY26. Apulki Healthcare's first cancer and cardiac hospital in Pune opened with a 60-year tenure and exclusive diagnostics rights; it is expected to mature to about INR20 crores in 2-3 years. With FY27 capex planned at INR5,000 million, the fixed assets in place by FY27 end should generate revenue from Rajasthan, Maharashtra, and retail without a proportional jump in operating cost.
Management's track record is mixed but directionally credible. On the November 2025 call, it promised 10 Rajasthan labs in November, 25 labs and 500 collection centers by December, and the rest by end-Q4 FY26; the May 2026 call shows installations largely complete, with full completion pushed to Q2 FY27 and revenue guidance of INR100-150 crores for FY27. Retail commitments were exceeded in scale: touch points reached 3,500+ versus an earlier count of 2,800, and retail revenue grew sixfold to INR60 crores, although its share is still only about 8% rather than the 8-10% initially guided for FY26. The misses are on core revenue and margins: FY26 revenue guidance of higher teens was not met, with 9M growth around 4%, and Q3 FY26 EBITDA margin slipped to 26% versus a 27% guided level, though full-year EBITDA margin recovered to 27.81%. Management also guided DSO below 120 days for FY27 from 139 days at Q4 FY26, and has recommended a INR2 per share dividend while planning INR5,000 million capex, indicating no distress; however, the CFO and CBO changes and repeated project slippages mean the burden of proof is on execution, not narrative.
The quantified path is that FY27 should see Rajasthan add INR100-150 crores of revenue, retail move to double-digit share and breakeven, and DSO fall below 120 days, while management expects to hold EBITDA margins at FY26 levels of 27.81% with possible operating leverage upside as assets mature. That implies PAT growth from higher revenue and lower interest cost, since collections improved sharply in H2 FY26, with Q4 alone collecting INR1,580 million, the highest quarterly figure. The kill shot is execution: if Maharashtra MRI sites continue to slip, if Rajasthan manpower costs persist without revenue, or if receivables remain above 120 days, the FY27 numbers will fall short; the single most important watchpoint is quarterly revenue recognition from the newly commissioned Rajasthan and Maharashtra sites, because the company has shown it can build capacity faster than government processes pay for it. The tension between earlier missed guidance and currently stable margins resolves as operational, not structural: the underlying asset base, accreditations, and contract visibility of INR6,000-7,000 crores over 5-7 years are intact, but the timing of capacity converting into revenue has repeatedly slipped. If the slip extends into FY28, the thesis downgrades from operating leverage to continued execution-miss.
companyname: Krsnaa Diagnostics Limited ticker: KRSNAA sector: Healthcare / Diagnostics Krsnaa Diagnostics Limited builds and runs diagnostic infrastructure for government health systems, then monetizes it through a parallel retail brand. Founded in 2010 and listed in 2021, the company operates a hub-and-spoke network of 190-plus CT and MRI centers, 147 pathology laboratories and over 4,700 patient collection centers across 18 states and union territories (Q4 FY26 call, May 2026). In FY26 it pr...
Read the full report →capex, new product segment, geographic expansion, order book surge
FY27 revenue growth guided at INR100-150 crores from Rajasthan and double-digit retail contribution driven by network expansion and Rajasthan ramp-up
Guidance no_datamixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Krsnaa Diagnostics Limited and 4,900+ companies.
5-day free pass. No card required.